$LEGNLegend Biotech Corp

📅 Upcoming

🕒 Recent(90d)

News

• Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series A
  Ying Huang has spent the past seven years building up one of the leading cancer cell therapy players. Now, just weeks after announcing his departure as Legend Biotech's CEO, Huang is stepping ...
  endpoints · 3h ago
• The top 12 companies hiring in biopharma now
  Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
  biospace · 5d ago
• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 6d ago
• Chutes & Ladders—Legend CEO departs without successor in place
  Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
  fiercebiotech · 11d ago
• J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
  The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
  biopharma_dive · 12d ago
• J&J secures right to take the helm in up to $925M Sail CAR T pact
  As part of the collaboration, Johnson & Johnson will have an exclusive option to acquire Sail Biomedicines for an additional $2.58 billion.
  biospace · 12d ago
• FDA scientists question Capricor data; Legend CEO steps down
  Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…
  biopharma_dive · 15d ago
• Legend CEO Ying Huang resigns; Carvykti chief named interim leader
  Legend Biotech, the developer of the blockbuster cancer therapy Carvykti, is in the market for a new CEO. Ying Huang stepped down Friday after serving as CEO since November 2020, Legend announced in a
  endpoints · 15d ago
• Legend Biotech CEO abruptly steps down without permanent replacement
  In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named.
  fiercebiotech · 15d ago
• Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
  Safety will be the key determinant of in vivo CAR T therapies, according to H.C. Wainwright’s Mitchel Kapoor, who noted that convenience and efficacy won’t be enough to impress investors in this sp…
  biospace · 15d ago